Valuation: Candel Therapeutics, Inc.

Market Cap 720M 631M 581M 539M 1.02B 68.7B 1.04B 6.95B 2.71B 33.72B 2.7B 2.65B 117B P/E 2026 *
-11x
P/E 2027 * -17.2x
Enterprise Value 720M 631M 581M 539M 1.02B 68.7B 1.04B 6.95B 2.71B 33.72B 2.7B 2.65B 117B EV / Sales 2026 *
-
EV / Sales 2027 * 13.7x
Free-Float
84.3%
Yield 2026 *
-
Yield 2027 * -
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-21 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-20 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-20 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-20 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-15 Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) RE
05-15 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (CAN-2409) In Localized Prostate Cancer Under Prolonged Follow-Up At AUA 2026 Annual Meeting CI
05-15 Candel Therapeutics, Inc. - Special Call
05-14 Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-29 Candel Therapeutics Enters Commercialization Agreement with EVERSANA for Potential U.S. Launch of Aglatimagene Besadenovec CI

Last Transcript: Candel Therapeutics, Inc.

1 day+2.03%
1 week-3.19%
Current month-2.62%
1 month+18.00%
3 months+99.80%
6 months+79.75%
Current year+77.52%
1 week 9.57
Extreme 9.57
11.36
1 month 7.93
Extreme 7.93
11.36
Current year 4.44
Extreme 4.44
11.36
1 year 4.35
Extreme 4.35
11.36
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 2020-08-31
Director of Finance/CFO 41 2024-01-11
Chief Tech/Sci/R&D Officer 57 2022-09-11
Director TitleAgeSince
Director/Board Member 80 2017-08-31
Director/Board Member 66 2020-08-31
Chairman 70 2021-07-14
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Chairman

2,199 0.0030%
06-29Free

Director

381 0.0005%
06-29Free

Director

1,331 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+2.03%-3.19%+101.00%+715.45% 720M
+1.08%+8.57%+3.61%+9.34% 49.92B
+0.40%-1.37%+418.11%+625.15% 40.23B
-0.52%+6.57%+26.79%-5.37% 34.55B
+3.97%+6.71%+28.41%+63.36% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-2.40%+1.60% - - 17.05B
+1.34%+5.68%+77.20%+141.51% 15.92B
-0.95%-0.38%+12.92%+17.96% 13.86B
+1.69%+3.09%+99.09%+99.19% 13.52B
Average +0.39%+5.53%+85.65%+188.75% 24.64B
Weighted average by Cap. +0.38%+6.42%+95.02%+142.90%

Financials

2026 *2027 *
Net sales - 52.65M 46.11M 42.47M 39.42M 74.86M 5.02B 75.87M 508M 198M 2.47B 198M 193M 8.55B
Net income -60.22M -52.74M -48.58M -45.09M -85.63M -5.74B -86.78M -581M -226M -2.82B -226M -221M -9.78B -42.95M -37.62M -34.65M -32.16M -61.07M -4.1B -61.89M -415M -161M -2.01B -161M -158M -6.97B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
26-07-06 US$10.03 +2.03% 1,074,746
26-07-02 US$9.830 -0.51% 1,550,102
26-07-01 US$9.880 -4.08% 1,875,643
26-06-30 US$10.30 -0.58% 2,943,146
26-06-29 US$10.36 +5.82% 1,488,455
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.830USD
Average target price
20.29USD
Spread / Average Target
+106.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock